4dmt announces first patients enrolled in 4front-1 phase 3 clinical trial evaluating 4d-150 in wet amd

Emeryville, calif., march 10, 2025 (globe newswire) -- 4d molecular therapeutics (nasdaq: fdmt, 4dmt or the company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that the first patients have been enrolled across multiple sites in the 4front-1 phase 3 clinical trial evaluating 4d-150 for the treatment of wet age-related macular degeneration (wet amd).
AMD Ratings Summary
AMD Quant Ranking